SCHEMBL8224740

SCHEMBL8224740

Nc1nc2ccccc2c2nn(Cc3ccccc3Cl)c(=O)n12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.51
▸ NOD2 Q9HC29 1/20 0.51
▸ NOD1 Q9Y239 1/20 0.51
▸ ADORA2A P29274 8/20 0.49
▸ LMNA P02545 3/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8221183 0.92 ADORA2A (0.47) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8224060 0.90 ADORA2A (0.45) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8220814 0.89 ADORA2A (0.46) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8221499 0.89 NPSR1 (0.48) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8217497 0.88 ADORA2A (0.49) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8221822 0.86 ADORA2A (0.63) ADORA2ALMNAALDH1A1POLBADORA1
SCHEMBL13341587 0.86 ADORA2A (0.47) ADORA2AMEN1KMT2AGAAMAPT
SCHEMBL13341672 0.85 ADORA2A (0.45) TNFNOD2NOD1ADORA2ATDP1
SCHEMBL8221845 0.84 ADORA2A (0.55) TNFNOD2NOD1ADORA2ALMNA
SCHEMBL8221012 0.83 ADORA2A (0.46) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
EP-2038285-B1 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORP (US) 2010-02-17 — — EP disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
WO-2008002596-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA3, ADORA2A, ADORA1 TNF 4494/4885NOD2 2017/4885NOD1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback